These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30653242)

  • 1. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
    Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
    Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
    Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
    Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
    J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
    JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
    Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
    J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant.
    Jacob D; Busciglio I; Burton D; Halawi H; Oduyebo I; Rhoten D; Ryks M; Harmsen WS; Camilleri M
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G505-G510. PubMed ID: 28814387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
    Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
    Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
    Ständer S; Spellman MC; Kwon P; Yosipovitch G
    Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
    Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study.
    Oncel I; Sancar M; Konuskan B; Arioz F; Tezcan S; Arman-Kandirmaz E; Parlak S; Gumeler E; Anlar B
    Pediatr Neurol; 2020 Sep; 110():59-63. PubMed ID: 32718528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
    Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
    PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
    Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
    Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.
    Zic JA; Straka BT; McGirt LY; Nian H; Yu C; Brown NJ
    JAMA Dermatol; 2018 Oct; 154(10):1221-1222. PubMed ID: 30140912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
    Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
    J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.